No Data
Hybio Pharmaceutical (300199.SZ): Chengji Pharmaceutical has been re-certified as a national high-tech enterprise.
On January 13, Gelonghui reported that Hybio Pharmaceutical (300199.SZ) announced that its wholly-owned subsidiary Gansu Chengji Biological Pharmaceutical Co., Ltd. (hereinafter referred to as "Chengji Pharmaceutical") recently received the "High-tech Enterprise Certificate" issued by the National High-tech Enterprise Recognition Management Work Leading Group Office, indicating that Chengji Pharmaceutical has passed the recognition as one of the first batch of high-tech enterprises for 2024. This recognition is a revalidation following the expiration of the original high-tech enterprise certificate of Chengji Pharmaceutical.
Hybio Pharmaceutical (300199.SZ): Liraglutide injection has obtained FDA approval certificate from the USA.
Gelonghui reported on December 24 that Hybio Pharmaceutical (300199.SZ) announced that on December 23, 2024, Shenzhen Hybio Pharmaceutical Co., Ltd. received notification from the USA Food and Drug Administration (referred to as "FDA") that the New Drug Abbreviated Application (referred to as "ANDA") for liraglutide injection filed jointly by Hybio Pharmaceutical and Hikma Pharmaceuticals USA, Inc. (referred to as "Hikma") has been approved. Liraglutide (liraglutide-1) is human glucagon-like peptide 1.
Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) Shares Climb 34% But Its Business Is Yet to Catch Up
Hybio Pharmaceutical (SZSE:300199) Is Carrying A Fair Bit Of Debt
Concept mining | Simgeglutide weight loss drug officially launched in China, multiple e-commerce platforms have gone online
The market has broad prospects
Investors Push Hybio Pharmaceutical (SZSE:300199) 4.1% Lower This Week, Company's Increasing Losses Might Be to Blame
Subdued Growth No Barrier To Hybio Pharmaceutical Co., Ltd. (SZSE:300199) With Shares Advancing 28%
No Data
